Skip to main content
Larkosis Pharma Logo
Cefpodoxime + Clavulanate Potassium

Category

Antibacterial

Form

Tablets

Strength

200mg / 125mg

CAS

87239-81-4 / 61177-45-5

Cefpodoxime + Clavulanate Potassium Tablets – Advanced Broad-Spectrum Antibacterial Therapy

Cefpodoxime + Clavulanate Potassium Tablets 200mg/125mg represent an advanced antibacterial formulation engineered to combat a wide range of bacterial infections, including those resistant to standard antibiotics. This dual-action combination merges the potent cephalosporin Cefpodoxime with the beta-lactamase inhibitor Clavulanate Potassium, ensuring enhanced efficacy against stubborn pathogens. Designed for clinical reliability and patient compliance, this antibacterial therapy offers targeted action, improved absorption, and extended bacterial coverage. It is widely used in respiratory tract infections, urinary tract infections, skin infections, and ENT infections. The formulation is backed by modern pharmaceutical innovation and global manufacturing standards.

Cefpodoxime + Clavulanate Potassium is a clinically important antibacterial combination used to address infections caused by beta-lactamase producing bacteria. Cefpodoxime is a third-generation cephalosporin that inhibits bacterial cell wall synthesis. Clavulanate Potassium acts as a beta-lactamase inhibitor, protecting Cefpodoxime from enzymatic degradation. The combination expands the antibacterial spectrum and improves outcomes where monotherapy may fail. This formulation is highly valued in modern antibacterial protocols due to reliability, convenience, and resistance management support.

Request Quote

Overview

  • Combination antibacterial tablet formulation.
  • Contains Cefpodoxime 200mg and Clavulanate Potassium 125mg.
  • Designed for resistant and mixed bacterial infections.
  • Oral dosage form with broad-spectrum antibacterial coverage.
  • Suitable for outpatient and hospital-based treatment use.

Introduction

  • Cefpodoxime + Clavulanate Potassium is a clinically important antibacterial combination used to address infections caused by beta-lactamase producing bacteria.
  • Cefpodoxime is a third-generation cephalosporin that inhibits bacterial cell wall synthesis.
  • Clavulanate Potassium acts as a beta-lactamase inhibitor, protecting Cefpodoxime from enzymatic degradation.
  • The combination expands the antibacterial spectrum and improves outcomes where monotherapy may fail.
  • This formulation is highly valued in modern antibacterial protocols due to reliability, convenience, and resistance management support.

Important Information

  • Formulated specifically to address infections caused by beta-lactamase producing bacteria.
  • Widely used in respiratory tract infections such as bronchitis and pneumonia.
  • Commonly prescribed for urinary tract infections, skin and soft tissue infections, and ENT infections.
  • Provides extended antibacterial spectrum with improved efficacy against resistant bacterial strains.
  • The 200mg Cefpodoxime and 125mg Clavulanate Potassium strength is optimized for balanced antibacterial activity and reduced resistance development.

Dosage

General

  • Adults: typically one tablet (200mg + 125mg) twice daily
  • Duration: usually 5 to 14 days depending on infection severity
  • Dose may vary depending on physician assessment and clinical response

Administration

  • Taken orally with food to improve absorption
  • Maintain consistent dosing intervals
  • Use only under medical supervision

Important

  • Do not skip doses
  • Do not stop treatment early unless advised by a doctor
  • Incomplete treatment may lead to bacterial persistence and antibiotic resistance

Storage

  • Store in a cool, dry place below 25°C
  • Protect from moisture and direct sunlight
  • Keep in original packaging until use
  • Keep out of reach of children

Shelf Life

  • Typical shelf life: 24 months from the date of manufacture
  • Do not use expired medication
  • Check packaging for manufacturing and expiry dates
  • Improper storage may reduce shelf life and therapeutic performance

Manufacturing

  • Manufactured in WHO-GMP certified facilities
  • Produced using high-quality active pharmaceutical ingredients
  • Advanced formulation technology ensures stable and effective dosage delivery
  • Strict quality control and batch testing support product consistency
  • Compliance with international pharmaceutical manufacturing standards
  • Cefpodoxime Proxetil reference CAS No.: 87239-81-4
  • Clavulanate Potassium reference CAS No.: 61177-45-5

Precautions

  • Use only under medical guidance
  • Inform doctor about allergies to cephalosporins or penicillins
  • Adjust dosage in renal impairment cases
  • Avoid alcohol during treatment
  • Not recommended for self-medication

Side Effects

  • Nausea
  • Diarrhea
  • Abdominal discomfort
  • Headache
  • Mild skin rash
  • Rare severe allergic reactions
  • Liver enzyme elevation
  • Clostridium difficile-associated diarrhea
  • Kidney function disturbances

Expert View

  • Cefpodoxime + Clavulanate Potassium represents a strategic advancement in antibacterial therapy.
  • The inclusion of Clavulanate enhances Cefpodoxime’s resistance profile and improves effectiveness against resistant strains.
  • Healthcare professionals often prefer this combination for empirical therapy in moderate infections.
  • It is also useful in cases with suspected beta-lactamase resistance and as step-down therapy after injectable antibiotics.
  • Its oral bioavailability and acceptable safety profile make it highly suitable for outpatient treatment and reduced hospitalization dependence.

Indications

  • Respiratory tract infections (bronchitis, pneumonia)
  • Urinary tract infections (UTIs)
  • Skin and soft tissue infections
  • Ear, nose, and throat infections
  • Moderate bacterial infections caused by resistant organisms
  • Empirical therapy in suspected beta-lactamase producing infections

Maintenance

  • Take strictly as prescribed by the healthcare provider
  • Maintain regular twice-daily dosing intervals
  • Complete the full antibacterial course even if symptoms improve early
  • Monitor symptom improvement during treatment
  • Avoid misuse to reduce the risk of bacterial resistance
  • Seek medical review if severe side effects or inadequate response occur

Why Choose

  • Broad-spectrum antibacterial coverage
  • Effective against resistant bacteria
  • Dual-action mechanism improves therapeutic success
  • Convenient oral dosage form
  • Clinically proven safety and efficacy
  • Suitable for multiple infection types

Frequently Asked Questions

Common product and supply questions.

What is cefpodoxime potassium clavulanate used for?+

Cefpodoxime + Clavulanate Potassium is used to treat bacterial infections such as respiratory, urinary tract, skin, and ENT infections. It works effectively against resistant bacteria due to its dual antibacterial action.

Is cefpodoxime a strong antibiotic?+

Yes, Cefpodoxime is a strong third-generation cephalosporin antibiotic. When combined with Clavulanate Potassium, it becomes more potent by overcoming bacterial resistance mechanisms, making it highly effective in treating moderate to severe infections.

Is cefpodoxime safe for kidneys?+

Cefpodoxime + Clavulanate Potassium is generally safe but requires dose adjustment in patients with kidney impairment. Medical supervision is essential to avoid accumulation and ensure safe antibacterial treatment.

What is the brand name for cefpodoxime 200 clavulanate 125 mg?+

Cefpodoxime + Clavulanate Potassium is marketed under various brand names globally, depending on the manufacturer. Always consult a pharmacist or healthcare provider for region-specific brand availability.

How many days should I take cefpodoxime 200 mg?+

The duration for Cefpodoxime + Clavulanate Potassium typically ranges from 5 to 14 days, depending on infection severity. Completing the full prescribed course is essential to prevent antibiotic resistance and ensure complete recovery.